Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fluorescent Antibody Technique, Direct | 1 | 2021 | 21 | 0.750 |
Why?
|
Pemphigoid, Bullous | 1 | 2021 | 13 | 0.750 |
Why?
|
Complement C3 | 1 | 2021 | 101 | 0.720 |
Why?
|
Skin | 2 | 2021 | 451 | 0.720 |
Why?
|
Sphingomyelin Phosphodiesterase | 4 | 2014 | 183 | 0.680 |
Why?
|
Immunoglobulin G | 1 | 2021 | 481 | 0.620 |
Why?
|
Autoantibodies | 1 | 2021 | 434 | 0.620 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 134 | 0.460 |
Why?
|
Interleukin-6 | 2 | 2014 | 330 | 0.450 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2012 | 67 | 0.400 |
Why?
|
Ceramides | 2 | 2012 | 578 | 0.380 |
Why?
|
Skin Neoplasms | 2 | 2022 | 375 | 0.270 |
Why?
|
Hemangiosarcoma | 1 | 2022 | 23 | 0.210 |
Why?
|
False Negative Reactions | 1 | 2021 | 63 | 0.190 |
Why?
|
Hydroa Vacciniforme | 1 | 2020 | 4 | 0.180 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 24 | 0.180 |
Why?
|
Lymphoproliferative Disorders | 1 | 2020 | 37 | 0.180 |
Why?
|
Signal Transduction | 3 | 2014 | 2689 | 0.170 |
Why?
|
Enzyme Inhibitors | 2 | 2014 | 659 | 0.170 |
Why?
|
Lower Extremity | 1 | 2021 | 153 | 0.170 |
Why?
|
Biopsy | 1 | 2021 | 540 | 0.160 |
Why?
|
Neoplasms, Fibrous Tissue | 1 | 2018 | 3 | 0.150 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2018 | 6 | 0.150 |
Why?
|
Hematoxylin | 1 | 2018 | 8 | 0.150 |
Why?
|
Databases, Factual | 1 | 2021 | 622 | 0.150 |
Why?
|
Elastic Tissue | 1 | 2018 | 28 | 0.150 |
Why?
|
Coloring Agents | 1 | 2018 | 66 | 0.150 |
Why?
|
Microscopy, Fluorescence | 1 | 2018 | 261 | 0.140 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 1465 | 0.140 |
Why?
|
Fluorescent Dyes | 1 | 2018 | 191 | 0.140 |
Why?
|
Magnets | 1 | 2015 | 4 | 0.130 |
Why?
|
Ferrosoferric Oxide | 1 | 2015 | 10 | 0.130 |
Why?
|
Reproducibility of Results | 1 | 2021 | 2077 | 0.130 |
Why?
|
Biomarkers | 1 | 2021 | 1593 | 0.130 |
Why?
|
Ferric Compounds | 1 | 2015 | 45 | 0.120 |
Why?
|
Niemann-Pick Diseases | 1 | 2014 | 6 | 0.120 |
Why?
|
Desipramine | 1 | 2014 | 47 | 0.120 |
Why?
|
MCF-7 Cells | 1 | 2014 | 80 | 0.120 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2014 | 138 | 0.120 |
Why?
|
Infant | 1 | 2021 | 2891 | 0.120 |
Why?
|
Nanostructures | 1 | 2015 | 112 | 0.120 |
Why?
|
HeLa Cells | 1 | 2014 | 237 | 0.110 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 196 | 0.110 |
Why?
|
Palmitic Acid | 1 | 2013 | 51 | 0.110 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 369 | 0.110 |
Why?
|
Protein Phosphatase 2C | 1 | 2012 | 3 | 0.100 |
Why?
|
Mitogen-Activated Protein Kinase 13 | 1 | 2012 | 8 | 0.100 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 434 | 0.100 |
Why?
|
Cell Line, Tumor | 2 | 2014 | 1851 | 0.100 |
Why?
|
Substrate Specificity | 1 | 2012 | 234 | 0.100 |
Why?
|
Cell Line | 2 | 2013 | 1752 | 0.100 |
Why?
|
Retrospective Studies | 2 | 2021 | 7277 | 0.100 |
Why?
|
Aged, 80 and over | 1 | 2021 | 4848 | 0.100 |
Why?
|
Ceramidases | 1 | 2011 | 47 | 0.100 |
Why?
|
Lipopolysaccharides | 1 | 2013 | 455 | 0.100 |
Why?
|
Kinetics | 1 | 2012 | 1047 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2012 | 791 | 0.090 |
Why?
|
Interleukin-1beta | 1 | 2010 | 88 | 0.090 |
Why?
|
RNA, Messenger | 1 | 2014 | 1664 | 0.090 |
Why?
|
Macrophages | 1 | 2013 | 647 | 0.090 |
Why?
|
Phosphorylation | 1 | 2012 | 1200 | 0.080 |
Why?
|
Cells, Cultured | 1 | 2014 | 2673 | 0.080 |
Why?
|
Sphingolipids | 1 | 2011 | 337 | 0.080 |
Why?
|
Humans | 7 | 2022 | 68618 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2010 | 626 | 0.070 |
Why?
|
Inflammation | 1 | 2013 | 1030 | 0.070 |
Why?
|
Aged | 1 | 2021 | 14862 | 0.060 |
Why?
|
Rats | 1 | 2012 | 5300 | 0.060 |
Why?
|
Middle Aged | 1 | 2021 | 21147 | 0.050 |
Why?
|
Adult | 1 | 2021 | 21403 | 0.050 |
Why?
|
Propranolol | 1 | 2022 | 103 | 0.050 |
Why?
|
Animals | 3 | 2013 | 20881 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2022 | 951 | 0.040 |
Why?
|
Male | 1 | 2021 | 37321 | 0.040 |
Why?
|
Female | 1 | 2021 | 38074 | 0.040 |
Why?
|
Porosity | 1 | 2015 | 63 | 0.030 |
Why?
|
X-Ray Diffraction | 1 | 2015 | 53 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 346 | 0.030 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 9 | 0.030 |
Why?
|
Toll-Like Receptor 2 | 1 | 2013 | 34 | 0.030 |
Why?
|
Toll-Like Receptor 4 | 1 | 2013 | 114 | 0.030 |
Why?
|
NF-kappa B | 1 | 2013 | 432 | 0.020 |
Why?
|
Intracellular Space | 1 | 2010 | 42 | 0.020 |
Why?
|
Serine | 1 | 2010 | 99 | 0.020 |
Why?
|
Extracellular Space | 1 | 2010 | 121 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2010 | 137 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 170 | 0.020 |
Why?
|
Lysosomes | 1 | 2010 | 136 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2010 | 326 | 0.020 |
Why?
|
Child | 1 | 2020 | 6405 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 710 | 0.020 |
Why?
|
Transfection | 1 | 2010 | 782 | 0.020 |
Why?
|
Blotting, Western | 1 | 2010 | 954 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 1745 | 0.020 |
Why?
|
Mutation | 1 | 2010 | 1213 | 0.020 |
Why?
|
Time Factors | 1 | 2010 | 4655 | 0.010 |
Why?
|
Mice | 1 | 2013 | 8474 | 0.010 |
Why?
|